[Outpatient breast cancer treatment after the hospital: what's next? - Adjuvant medical therapies, management of side effects and common fears, planing and coordination of optimal follow-up care in view of current guidelines]
- PMID: 33775135
- DOI: 10.1024/0040-5930/a001250
[Outpatient breast cancer treatment after the hospital: what's next? - Adjuvant medical therapies, management of side effects and common fears, planing and coordination of optimal follow-up care in view of current guidelines]
Abstract
Outpatient breast cancer treatment after the hospital: what's next? - Adjuvant medical therapies, management of side effects and common fears, planing and coordination of optimal follow-up care in view of current guidelines Abstract. Following successful breast cancer surgery patients will generally be facing a certain prolonged period of medical treatment accompanied by several years of follow-up care, usually in the setting of a private practice or outpatient clinic. These medical treatments, which have proven by evidence to substantially reduce the risk of breast cancer recurrence and thereby significantly added to the boost in overall prognosis of this disease, are discussed in the light of current international treatment guidelines in this article. The standard approach to modern medical therapies is outlined on the basis of clinical pathological risk factors and tumor biology for different breast cancer subtypes (e. g. luminal, HER2-positiv, triple negativ / basal-like) accordingly. We hereby focus particularly upon the management of therapy-induced side effects, typical substance-specific toxicities as well as offering remedy to common fears and myths concerning medical breast cancer treatment. Last but not least we describe our perspective of the "ideal outpatient follow-up care", outlining a time-plan, implementing interdisciplinary expertise and stressing the necessity for good teamwork and interaction among all health care specialists involved, to optimise patient comfort and outcome.
Zusammenfassung. Nach der operativen Behandlung des Mammakarzinoms folgt in der Regel eine längerfristige medikamentöse Therapie sowie anschliessend oder zeitgleich eine mehrjährige ambulante Tumornachsorge in der Praxis. Diese medikamentösen Therapien, welche das Rezidivrisiko des Mammakarzinoms nachweislich senken und in ihrer Summe zu einer erheblichen Verbesserung der Prognose dieser Erkrankung geführt haben, werden im folgenden Artikel anhand aktuellster Empfehlungen internationaler Fachgesellschaften unter Berücksichtigung der verschiedenen Tumorbiologien und Subtypen (luminal, HER2-positiv, triple-negativ / basal) entsprechend erläutert. Ein besonderer Fokus wird hierbei auch auf die Bewältigung der häufig auftretenden Ängste und praxisrelevanten, therapieassoziierten Nebenwirkungen gelegt. Abschliessend beschreiben wir aus unserer Perspektive die Grundzüge einer erfolgreichen interdisziplinären Mammakarzinom-Nachsorge nach heutigem Standard.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
